Research and services aimed at extending healthspan, from metabolic and cellular-health research to longevity clinics.
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
Automated from official records5 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
Automated from official records3 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records8 sources1 min read
Phase 2, The University of Texas Health Science Center at San Antonio. Conditions: Aging; Functional Decline. Interventions: Dapagliflozin 10Mg Oral Tablet; Semaglutide oral; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Phase 2, Atria Research and Global Health Institute (ARGHI). Conditions: Longevity; Preventive Medicine; Biological Ageing. Interventions: Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
Phase 2, Sheba Medical Center. Conditions: Healthy Aging. Interventions: AgeBiotics AB-01; AgeBiotics AB-02; Metformin; semaglutide; empagliflozin. Investigational: trial-stage therapies are not approved for the use studied.
